Barclays PLC has disclosed a small ownership stake in Core Scientific Inc. The filing reports that Barclays beneficially owns 1,302,387 shares of Core Scientific common stock, representing 0.42% of the outstanding class.
Barclays reports 1,298,420 shares with sole voting and dispositive power and 3,967 shares with shared voting and dispositive power. The shares are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Core Scientific.
Core Scientific director Jeffrey David Booth received 18,575 restricted stock units of common stock on February 4, 2026, as reported in a Form 4 filing. The grant was priced at $0 per share and will vest in full on February 3, 2027, if he continues serving as a non-employee director through that date. Following this award, Booth beneficially owns 214,262 shares of Core Scientific common stock directly.
Core Scientific, Inc. director Jordan Levy reported receiving an award of 18,575 shares of common stock on February 4, 2026 at a price of $0, reflecting a restricted stock unit grant. Following this grant, he beneficially owns 325,462 shares directly.
The restricted stock units will vest in full on February 3, 2027, provided Levy continues to serve as a non-employee director through that date.
Core Scientific, Inc. director Elizabeth Crain received a grant of 18,575 shares of common stock as restricted stock units. The award was reported as acquired at a price of $0 per share on February 4, 2026, increasing her directly held beneficial ownership to 65,348 shares.
The RSUs will vest in full on February 3, 2027, if she continues to serve as a non-employee director through that date. Until vesting, the units represent a right to receive shares rather than currently transferable stock.
Core Scientific, Inc. director Rozov Yadin reported an award of 18,575 shares of common stock on February 4, 2026, coded as an acquisition at a price of $0 per share. This reflects a grant rather than an open-market purchase.
The award represents a restricted stock unit grant that will vest in full on February 3, 2027, if Yadin continues to serve as a non-employee director through that date. After this grant, Yadin beneficially owns 454,162 shares of Core Scientific common stock in direct ownership.
Core Scientific director Eric Stanton Weiss received a new equity grant. On February 4, 2026, he was awarded 18,575 shares of Core Scientific common stock at a price of $0 per share, bringing his directly held stake to 245,262 shares.
The award is structured as restricted stock units that will vest in full on February 3, 2027, provided Weiss continues to serve the company as a non-employee director through that date.
Core Scientific, Inc. CEO and director reported an amendment to a prior insider transaction report. On January 29, 2026, 274,554 shares of common stock were withheld at $18.79 per share to cover tax obligations from vesting restricted stock units. After this withholding, the reporting person beneficially owned 4,131,150 shares directly. The amendment corrects an earlier filing that had inadvertently reported 274,404 shares withheld on January 23, 2026.
Core Scientific CEO Adam Taylor reported a tax-related share withholding. On 01/23/2026, 274,404 shares of Core Scientific common stock were withheld at a price of $18.79 per share to cover withholding tax obligations tied to the vesting of restricted stock units.
After this automatic withholding, Taylor directly beneficially owned 4,131,300 shares. The transaction is coded "F," indicating it was associated with equity award vesting rather than an open-market sale.
Two Seas Capital and related reporting persons filed an amended ownership report for Core Scientific, Inc., disclosing beneficial ownership of 22,472,467 shares of common stock, or about 7.2% of the company. This total includes 313,646 shares issuable upon exercise of warrants and options to purchase 5,077,600 shares at an exercise price of $17 that expire on February 20, 2026. The position is held through various funds and accounts that have delegated sole voting and investment power to Two Seas Capital.
The filing states the securities were acquired for investment purposes in the ordinary course of business because they were viewed as an attractive opportunity. The reporting persons may engage with Core Scientific’s management, board, other shareholders, and market participants on topics such as business strategy, capital allocation, governance, and environmental and social matters. They also indicate they may increase or decrease their position or use derivatives and hedging strategies to adjust their economic exposure over time.
Situational Awareness entities and two individuals filed a Schedule 13D reporting shared beneficial ownership of 17,682,918 shares of Core Scientific, Inc. common stock, representing 5.8% of the class based on 305,408,442 shares outstanding as of August 5, 2025. The filing states the Fund used $213,190,431.12 of working capital to acquire the shares, largely through a series of open-market purchases in July and August 2025 at prices reported between $13.189 and $14.9047 per share. The reporting persons say the stock was acquired for investment because they considered it undervalued and they reserve the right to buy, sell, hedge, or communicate with other stakeholders, but currently have no present plan to effect specific corporate changes.